Structure-based design of novel inhibitors of the MDM2-p53 interaction - Wikidata - wikimedia - TriplyDB

Structure-based design of novel inhibitors of the MDM2-p53 interaction

Structure-based design of novel inhibitors of the MDM2-p53 interaction

http://www.wikidata.org/entity/Q27678657

about

Chemical Variations on the p53 Reactivation Theme Inhibition of nutlin-resistant HDM2 mutants by stapled peptides In vitro selection of mutant HDM2 resistant to Nutlin inhibition Structural characterization and inhibition of the Plasmodium Atg8–Atg3 interaction Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development The structure of an MDM2-Nutlin-3a complex solved by the use of a validated MDM2 surface-entropy reduction mutant 8-Triazolylpurines: Towards Fluorescent Inhibitors of the MDM2/p53 Interaction Design, Synthesis and Evaluation of 2,5-Diketopiperazines as Inhibitors of the MDM2-p53 Interaction Diaryl- and triaryl-pyrrole derivatives: inhibitors of the MDM2-p53 and MDMX-p53 protein-protein interactions†Electronic supplementary information (ESI) available: Experimental details for compound synthesis, analytical data for all compounds and in Organocatalytic, diastereo- and enantioselective synthesis of nonsymmetric cis-stilbene diamines: a platform for the preparation of single-enantiomer cis-imidazolines for protein-protein inhibition.Discovery of Potent and Simplified Piperidinone-Based Inhibitors of the MDM2-p53 Interaction.MDM2, MDMX and p53 in oncogenesis and cancer therapy Targeting protein-protein interactions as an anticancer strategy Design, synthesis and biological evaluation of sulfamide and triazole benzodiazepines as novel p53-MDM2 inhibitors SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression A novel drug discovery strategy: mechanistic investigation of an enantiomeric antitumor agent targeting dual p53 and NF-κB pathways.Identification of novel rab27a/melanophilin blockers by pharmacophore-based virtual screening.Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.Small-molecule MDM2-p53 inhibitors: recent advances.How To Design a Successful p53-MDM2/X Interaction Inhibitor: A Thorough Overview Based on Crystal Structures.AlphaSpace: Fragment-Centric Topographical Mapping To Target Protein-Protein Interaction Interfaces.Markov models of the apo-MDM2 lid region reveal diffuse yet two-state binding dynamics and receptor poses for computational docking.Diastereomeric spirooxindoles as highly potent and efficacious MDM2 inhibitors A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice.Capsaicin mediates cell cycle arrest and apoptosis in human colon cancer cells via stabilizing and activating p53.Targeting the ubiquitin-mediated proteasome degradation of p53 for cancer therapy.Resistance acquisition to MDM2 inhibitors.Targeting p53-MDM2-MDMX loop for cancer therapy.Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapy: Progress and Challenges.Coccoquinones A and B, new anthraquinone derivatives produced by Staphylotrichum coccosporum PF1460.Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.Pharmacological activation of wild-type p53 in the therapy of leukemia.Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma.Synthesis of spiro[isoindole-1,5'-isoxazolidin]-3(2H)-ones as potential inhibitors of the MDM2-p53 interaction.Microsecond simulations of mdm2 and its complex with p53 yield insight into force field accuracy and conformational dynamics.MDM2 antagonists synergize broadly and robustly with compounds targeting fundamental oncogenic signaling pathways.Spiro-oxindoles as a Promising Class of Small Molecule Inhibitors of p53-MDM2 Interaction Useful in Targeted Cancer Therapy.Reviving the guardian of the genome: Small molecule activators of p53.Efficient synthesis of RITA and its analogues: derivation of analogues with improved antiproliferative activity via modulation of p53/miR-34a pathway.The use of ion mobility mass spectrometry to probe modulation of the structure of p53 and of MDM2 by small molecule inhibitors

P2860

Q26749008-A218C942-6AE5-4DD8-9AAB-4E1F058DE34A Q27301404-A2DB5C0F-9649-4A49-B66D-AE69AE8E42E5 Q27322456-C089E43E-347D-42D6-A404-CABD34B5C611 Q27673186-3C7035F8-2F5A-4888-A794-F880947FFB61 Q27684199-D4C54CE0-8634-4068-9FFE-E9EADA5F1380 Q27685287-FE7B6DA7-1F32-4C88-9EDB-71298839703C Q28547009-8F612BB3-758E-45D6-BCA7-64F4E3412A04 Q28548694-2FF42DB6-B5E7-4AF9-A232-F81F231543FA Q30670705-1E56B62C-08DE-4179-BE31-D9764CC53445 Q33998827-F373D443-A095-445E-8982-0C058938FE8C Q34063712-E16E0513-0FB2-43A9-BED6-6F1C8FB75245 Q34166049-50313AD3-0B37-478F-811C-3AA7AEA82D82 Q34347892-07D4831B-3A0A-402E-86D3-4B37BD86D07F Q34358585-30ECF89D-1D10-4AB2-9C55-831AAC52B603 Q34584722-DEB068FA-B03D-479C-8060-4621048A4ABF Q34786578-FF57AEF2-154D-426F-9013-52FF77B128D7 Q35057299-4CDCBFCE-B6FD-4E5A-8853-8CAABEDB905C Q35087851-34B11058-3EED-495C-A1D4-49F541B186AF Q35617077-7D1D9AF0-9E32-405B-92E5-025E08287797 Q35871210-A6EA5391-2751-42A9-81B5-0DE18005E088 Q35997296-E74FF267-2E6A-451D-92A5-485274DACC76 Q37188955-F5835B9F-1472-458B-97FC-EE60ED698AF2 Q37249642-E5F2D9EE-99F9-42B4-9D73-917976EB4952 Q37432745-DE775BD1-05DE-456F-A687-B39F7A364575 Q37642359-FE50BDA6-7BD7-4447-9C06-8776DF260DF0 Q38059739-A62B25E0-3E0E-45EE-99F0-52A4427801DF Q38238600-1D178091-61E0-42CE-9859-EED166330302 Q38247168-CD29659D-3B46-4AD8-803D-FE554AEE4170 Q38749151-0B2D003B-0AD3-4465-95EF-3E2272CC93F8 Q38828141-FAB3A1B9-EA29-4F2B-A20E-0BB288AF37A9 Q38865504-44A65F0C-4BB7-4146-8080-D4B160C0B609 Q38872029-6B69AF1F-88D9-4890-A0DA-5D344B955953 Q38890690-FAD63C28-01D0-4809-9895-B2863F00E427 Q38987994-1C25AE16-142A-4CB4-8147-E7EBB82B2BB2 Q38988816-8FC19CE4-9653-4F48-B630-FC74B30716F9 Q38997002-FC1D80E2-A1CA-462F-B9BD-CD3DB6E20822 Q39036213-2F5332D1-3A5B-43AB-805A-8D6745FBE794 Q39205536-A16413F0-E225-4810-B07F-712285FD1754 Q39244957-3A453DE5-D2BF-4401-81B8-A97F511C66BB Q40688335-38AAC6FA-6DDE-49F9-BD8A-DE5F8E70E733

P2860

Structure-based design of novel inhibitors of the MDM2-p53 interaction

http://www.wikidata.org/entity/Q27678657

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Structure-based design of novel inhibitors of the MDM2-p53 interaction

@ast

Structure-based design of novel inhibitors of the MDM2-p53 interaction

@en

Structure-based design of novel inhibitors of the MDM2-p53 interaction

@nl

type

label

Structure-based design of novel inhibitors of the MDM2-p53 interaction

@ast

Structure-based design of novel inhibitors of the MDM2-p53 interaction

@en

Structure-based design of novel inhibitors of the MDM2-p53 interaction

@nl

prefLabel

Structure-based design of novel inhibitors of the MDM2-p53 interaction

@ast

Structure-based design of novel inhibitors of the MDM2-p53 interaction

@en

Structure-based design of novel inhibitors of the MDM2-p53 interaction

@nl

P1433

Q27678657-BB280875-15E6-4B32-834E-4BC37D9D025B

P1476

Q27678657-E5497E69-A792-44E7-ABB9-82FC4F58B57C

P2093

Q27678657-01946394-47CF-4E9A-B25A-49EC2B5FB550

Q27678657-041AC1B8-FAD1-4D33-B5BF-DB4511D0D685

Q27678657-0BCD01F3-113E-4E8C-B090-BE899CC80C84

Q27678657-0DCDBD29-D99E-40C9-B7EF-5137916373F8

Q27678657-1157EC85-8EDC-4576-B84E-00A3754C4BEF

Q27678657-15277F76-1B7B-442E-A639-5B744927624E

Q27678657-1A889084-C509-4099-BBCC-97C55D4A702E

Q27678657-1CDA3E9C-304F-43C3-BC94-02DC93A9C817

Q27678657-23A17862-D85D-42FE-A012-7EB6DEAA5C20

Q27678657-241A1201-CB67-4F1E-BCEE-5FCBD1801A74

P304

Q27678657-3BAAC348-3083-49A0-8F81-46E87EA5810F

P31

Q27678657-7C44EFCA-2E2D-482A-8F70-D2835520A1AD

P3181

Q27678657-71815ECB-FACF-419D-91EA-9DEE307E6CA9

P356

Q27678657-FB1EE114-FB8D-4C50-85A0-29B733C5FF94

P407

Q27678657-CF0EA29C-9BB8-4DE5-936A-B3ED8B1BB912

P433

Q27678657-13A453FA-AB27-44DA-B5E1-9EB93A7D4D35

P478

Q27678657-5471D732-B382-483F-ABF9-175AFA08F0F8

P577

Q27678657-3EE7457E-A5FF-4FE8-8094-BFF633A96A16

P5875

Q27678657-53CD775C-D666-49DD-BF43-D0E1C4BFC12B

P698

Q27678657-DF134C8E-0BA5-4EB5-A6DB-C6E24024DBF7

P3181

P356

P1433

Journal of Medicinal Chemistry

P1476

Structure-based design of novel inhibitors of the MDM2-p53 interaction

@en

P2093

Ada Chen

http://www.w3.org/2001/XMLSchema#string

Alexander M Long

http://www.w3.org/2001/XMLSchema#string

Anne Y Saiki

http://www.w3.org/2001/XMLSchema#string

Brian M Fox

http://www.w3.org/2001/XMLSchema#string

Daqing Sun

http://www.w3.org/2001/XMLSchema#string

Darin Gustin

http://www.w3.org/2001/XMLSchema#string

David Chow

http://www.w3.org/2001/XMLSchema#string

David J Kopecky

http://www.w3.org/2001/XMLSchema#string

Dongyin Yu

http://www.w3.org/2001/XMLSchema#string

Felix Gonzalez-Lopez De Turiso

http://www.w3.org/2001/XMLSchema#string

P304

4936-54

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1648270

http://www.w3.org/2001/XMLSchema#string

P356

10.1021/JM300354J

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

55

http://www.w3.org/2001/XMLSchema#string

P577

2012-06-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

224823219

http://www.w3.org/2001/XMLSchema#string

P698

22524527

http://www.w3.org/2001/XMLSchema#string